Back to Pycnogenol (Maritime Pine Bark)

Timing & pharmacokinetics

How long does Pycnogenol (Maritime Pine Bark) take to work?

Onset timing for Pycnogenol (Maritime Pine Bark) varies in the clinical literature. Onset timing is not well-quantified in our dataset, refer to clinical citations on the main entry.

Onset

Half-life

Duration

Timing

AM

Key facts

typical dose
100–200 mg
dose frequency
1-2 doses
timing
AM
with food
with meal
safety score
5/5
evidence grade
B
class
neuroprotective
PubMed citations
580
legal status (US)
Over-the-counter
legal status (UK)
Over-the-counter
legal status (EU)
Over-the-counter
legal status (AU)
Over-the-counter
primary mechanism
A complex of procyanidins (oligomeric proanthocyanidins), bioflavonoids, and organic acids.

Onset window

Pycnogenol (Maritime Pine Bark) onset times in the published literature vary widely. Refer to the citations on the main Pycnogenol (Maritime Pine Bark) entry for compound-specific pharmacokinetic data.

Food effect: Taking with food slows absorption but improves tolerance. Onset shifts 30–60 minutes later than empty-stomach dosing.

Half-life and dosing frequency

Half-life is not characterised in our dataset.

Acute vs. chronic effect

Some nootropics work the first time you take them (Pycnogenol (Maritime Pine Bark) may or may not). Others, adaptogens, racetams, and most botanicals targeting BDNF or NGF pathways, require 2–4 weeks of daily dosing before the full effect emerges.

If you don’t feel anything after a single dose and the compound is in the chronic-effect category, that is normal, extend the trial to 2–4 weeks before evaluating. If it is in the acute category and you feel nothing, consider dose, vendor sourcing, or whether the compound matches your goal.

Mechanism, safety, and citations for Pycnogenol (Maritime Pine Bark) are on the main reference page, see Pycnogenol (Maritime Pine Bark). For full dose protocol see Pycnogenol (Maritime Pine Bark) dosage. To check for stack-level pharmacokinetic conflicts, use the interaction checker.

Onset and pharmacokinetic data reflect the published literature for healthy adults at typical doses. Individual variation in absorption, metabolism (CYP genotype), and gut transit can shift onset by ±50%. This page is informational and not medical advice. See our full disclaimer.